RU2561873C2 - Применение антагонистов опиоидных рецепторов при заболеваниях желудочно-кишечного тракта - Google Patents

Применение антагонистов опиоидных рецепторов при заболеваниях желудочно-кишечного тракта Download PDF

Info

Publication number
RU2561873C2
RU2561873C2 RU2012115450/15A RU2012115450A RU2561873C2 RU 2561873 C2 RU2561873 C2 RU 2561873C2 RU 2012115450/15 A RU2012115450/15 A RU 2012115450/15A RU 2012115450 A RU2012115450 A RU 2012115450A RU 2561873 C2 RU2561873 C2 RU 2561873C2
Authority
RU
Russia
Prior art keywords
compound
opioid
dose
day
pharmaceutically acceptable
Prior art date
Application number
RU2012115450/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2012115450A (ru
Inventor
Ричард М. Вудворд
Original Assignee
Адолор Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2561873(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Адолор Корпорейшн filed Critical Адолор Корпорейшн
Publication of RU2012115450A publication Critical patent/RU2012115450A/ru
Application granted granted Critical
Publication of RU2561873C2 publication Critical patent/RU2561873C2/ru

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2012115450/15A 2009-09-18 2010-09-17 Применение антагонистов опиоидных рецепторов при заболеваниях желудочно-кишечного тракта RU2561873C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24361609P 2009-09-18 2009-09-18
US61/243,616 2009-09-18
PCT/US2010/049311 WO2011035142A1 (en) 2009-09-18 2010-09-17 Use of opioid receptor antagonist for gastrointestinal tract disorders

Publications (2)

Publication Number Publication Date
RU2012115450A RU2012115450A (ru) 2013-10-27
RU2561873C2 true RU2561873C2 (ru) 2015-09-10

Family

ID=43216894

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012115450/15A RU2561873C2 (ru) 2009-09-18 2010-09-17 Применение антагонистов опиоидных рецепторов при заболеваниях желудочно-кишечного тракта

Country Status (19)

Country Link
US (1) US20110071163A1 (https=)
EP (1) EP2477627B1 (https=)
JP (1) JP5797655B2 (https=)
KR (1) KR20120092592A (https=)
CN (2) CN102695508A (https=)
AU (1) AU2010295464B2 (https=)
BR (1) BR112012006069A8 (https=)
CA (1) CA2774021A1 (https=)
CL (1) CL2012000676A1 (https=)
CO (1) CO6531453A2 (https=)
HK (1) HK1210959A1 (https=)
IL (1) IL218679A0 (https=)
MX (1) MX342548B (https=)
NZ (1) NZ598783A (https=)
PE (1) PE20120991A1 (https=)
RU (1) RU2561873C2 (https=)
TW (1) TW201118084A (https=)
WO (1) WO2011035142A1 (https=)
ZA (1) ZA201201954B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2760880B1 (en) 2012-12-28 2015-07-08 Instytut Medycyny Doswiadczalnej I Klinicznej Peptidomimetics and their application
AR108535A1 (es) 2016-05-20 2018-08-29 Esteve Labor Dr Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor
CN106117190B (zh) * 2016-06-21 2019-03-29 山东川成医药股份有限公司 一种倍福普兰的合成方法
CA3124115A1 (en) 2019-01-04 2020-07-09 Aether Therapeutics Inc. Method for treating drug or alcohol dependency

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255152A1 (en) * 2002-09-19 2008-10-16 Maria-Jesus Blanco-Pillado Diaryl ethers as opioid receptor antagonists

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191771A (en) * 1974-09-06 1980-03-04 Eli Lilly And Company Analgesic method using 1,3,4-trisubstituted-4-arylpiperidines
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
US4992450A (en) * 1987-04-16 1991-02-12 Eli Lilly And Company Piperidine opioid antagonists
US5319087A (en) * 1987-04-16 1994-06-07 Eli Lilly And Company Piperidine opioid antagonists
US5064834A (en) * 1987-04-16 1991-11-12 Eli Lilly And Company Piperidine opioid antagonists
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5270328A (en) * 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
ES2188657T3 (es) 1994-04-22 2003-07-01 Yamanouchi Pharma Co Ltd Sistema para la liberacion especifica en el colon de un farmaco.
US5378448A (en) * 1994-06-07 1995-01-03 Lin; Hsing K. Process for removing selenium from sulfur
TW490465B (en) * 1994-11-24 2002-06-11 Janssen Pharmaceutica Nv Enterokinetic benzamide, the preparation process and the pharmaceutical compositions thereof
ES2171839T3 (es) * 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
MXPA01003197A (es) 1998-09-28 2004-04-21 Warner Lambert Co Suministro enterico y colonico utilizando capsulas de chpm.
US6436959B1 (en) * 1998-12-23 2002-08-20 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)]aminobenzamides
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
RU2695274C3 (ru) * 1999-10-15 2020-11-09 Сукампо Аг Новые композиции и способы их стабилизации
ES2226933T3 (es) * 1999-11-01 2005-04-01 John Rhodes Composicion para tratar el estreñimiento y el sindrome del intestino irritable.
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
JP4340437B2 (ja) * 2000-10-31 2009-10-07 レンセラール ポリテクニック インスティチュート 8−カルボキサミド−2,6−メタノ−3−ベンズアゾシン
EP1420794B1 (en) * 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
ES2654819T3 (es) * 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
BRPI0317740B8 (pt) * 2002-12-27 2021-05-25 Sucampo Ag uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1
US7396943B2 (en) * 2003-03-07 2008-07-08 Eli Lilly And Company Opioid receptor antagonists
BRPI0417156A (pt) * 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
CN1894240A (zh) * 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
EP1727788B1 (en) * 2004-03-12 2010-07-28 Eli Lilly And Company Opioid receptor antagonists
EP1730140B1 (en) * 2004-03-12 2008-06-25 Eli Lilly And Company Opioid receptor antagonists
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006126529A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体
CA2637274C (en) * 2006-01-24 2013-06-04 R-Tech Ueno, Ltd. Soft-gelatin capsule formulation
MY145633A (en) * 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc 8-氮雜雙環〔3.2.1〕辛烷化合物之結晶型
JP2011500686A (ja) * 2007-10-18 2011-01-06 アイコ バイオテクノロジー オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤
ES2402749T3 (es) * 2007-12-11 2013-05-08 Theravance, Inc. Derivados de 3-carboxipropil-aminotetralina como antagonistas del receptor de opioide mu
TWI449685B (zh) * 2008-12-10 2014-08-21 Theravance Inc 3-羧基丙基-胺基四氫化萘化合物之結晶型
US9119848B2 (en) * 2009-12-04 2015-09-01 Alkermes Pharma Ireland Limited Morphinan derivatives for the treatment of drug overdose

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255152A1 (en) * 2002-09-19 2008-10-16 Maria-Jesus Blanco-Pillado Diaryl ethers as opioid receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRIEDMAN J.D., Opioid antagonists in the treatment of opioid-induced consitipation and pruritus, Ann. Pharmacotherapy, 2001, 35, pp 85-91. CHANG HY et al.,Opioid-induced bowel dysfunction.,Current Treat Options. Gastroenterol., 2008, 11, pp. 1-8 *

Also Published As

Publication number Publication date
JP5797655B2 (ja) 2015-10-21
ZA201201954B (en) 2012-11-28
NZ598783A (en) 2013-07-26
BR112012006069A2 (pt) 2016-03-29
IL218679A0 (en) 2012-05-31
CO6531453A2 (es) 2012-09-28
RU2012115450A (ru) 2013-10-27
CL2012000676A1 (es) 2012-10-19
MX342548B (es) 2016-10-04
KR20120092592A (ko) 2012-08-21
AU2010295464A1 (en) 2012-04-12
CA2774021A1 (en) 2011-03-24
CN104958298A (zh) 2015-10-07
TW201118084A (en) 2011-06-01
MX2012003310A (es) 2012-07-17
EP2477627A1 (en) 2012-07-25
CN102695508A (zh) 2012-09-26
EP2477627B1 (en) 2018-08-15
JP2013505260A (ja) 2013-02-14
HK1210959A1 (en) 2016-05-13
AU2010295464B2 (en) 2015-11-26
US20110071163A1 (en) 2011-03-24
BR112012006069A8 (pt) 2017-10-10
WO2011035142A1 (en) 2011-03-24
PE20120991A1 (es) 2012-08-01

Similar Documents

Publication Publication Date Title
DK2574167T3 (en) LIQUID NOSE SPRAY CONTAINING low-dose naltrexone
AU2009244805B2 (en) Oral administration of peripherally-acting opioid antagonists
AU2016244249B2 (en) Systems and methods for treating an opioid-induced adverse pharmacodynamic response
TWI473614B (zh) Anti-analgesic inhibitors
WO2017066488A1 (en) Treating pain using a composition comprising an opioid and an antiemetic
WO2007120485A2 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
RU2561873C2 (ru) Применение антагонистов опиоидных рецепторов при заболеваниях желудочно-кишечного тракта
AU2019203694A1 (en) Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
KR101971412B1 (ko) 정맥 내 투여용 이부프로펜의 투여
US20100010029A1 (en) Acute Pain Medications Based on Fast Acting Diclofenac-Opioid Combinations
JP2006131545A (ja) 神経因性疼痛治療剤
US10874658B2 (en) Sublingual opioid formulations containing naloxone
JP2013040206A (ja) 消化器系の運動をイパモレリンを用いて刺激する方法
US20250345324A1 (en) Combination formulations of naloxone and atipamezole
WO2015191686A1 (en) Methods of administering methylnaltrexone

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20160219

MM4A The patent is invalid due to non-payment of fees

Effective date: 20190918